{"id":"5b1b831293aa","type":"article","url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","title":"HFA-consensus: gestructureerde aanpak van recent ontstane cardiomyopathie","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag115","source_url":"https://doi.org/10.1093/eschf/xvag115","authors":["Hadi Skouri","Amr Abdin","Wilfried Mullens","Chiara Bucciarelli Ducci","Randall C Starling","Peter Van der Meer","Gianluigi Savarese","Tuvia Ben Gal","Antoni Bayes-Genis","Stephane Heymans","Karin Klingel","Sanjay K Prasad","Dimitrios Farmakis","Ovidiu Chioncel","Arsen Ristic","Giuseppe Rosano","Petar Seferovic","Piotr Ponikowiski","Marco Metra","Carsten Tschöpe"],"significance":7,"published":"2026-05-01","source_date":"2026-05-05","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/diagnose-hartfalen-stappenplan/","https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"The Heart Failure Association of the ESC issues a consensus statement on the evaluation and management of recent-onset non-ischaemic cardiomyopathy. The framework rests on two prognostic axes — potential for left ventricular reverse remodelling and risk of sudden cardiac death — and recognises four LVEF-trajectory categories. Diagnostics combine echocardiography, CMR, genetic testing, biomarkers and early treatment response. The management algorithm emphasises early initiation of guideline-directed medical therapy, re-assessment at 3 and 6 months, and individualised decisions on ICD, CRT, ablation and transcatheter valve repair.","created":"2026-07-03T10:32:49Z","updated":"2026-07-03T13:31:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De Heart Failure Association van de ESC publiceert een consensusdocument voor de evaluatie en behandeling van recent ontstane (niet-ischemische) cardiomyopathie. De aanpak is gebaseerd op twee prognostische assen: het potentieel voor reverse remodeling en het risico op plotse hartdood. Vier trajectcategorieën worden gedefinieerd op basis van LVEF-evolutie. Diagnostiek combineert echocardiografie, cardiale MR, genetisch onderzoek, biomarkers en vroege behandelrespons. Het managementalgoritme benadrukt vroege start van GDMT, herevaluatie op 3 en 6 maanden, en geïndividualiseerde overweging van ICD, CRT, ablatie en TEER.","abstract_original":"Recent-onset cardiomyopathy represents a clinically dynamic and potentially reversible clinical framework of non-ischaemic cardiomyopathy, characterized by high variability in left ventricular (LV) function and arrhythmic risk. This clinical consensus statement provides a structured diagnostic and therapeutic approach based on two prognostic axes: the potential for LV reverse remodelling (LVRR) and the risk of sudden cardiac death (SCD). We operationalize four trajectories in the LV evolution, ranging from recovered LV ejection fraction (LVEF) to persistently reduced LVEF. Multimodal stratification including echocardiography, cardiac magnetic resonance, genetic profiling, biomarkers, and early treatment response allows tailored decision-making on pharmacological and device-based therapies. We propose a unified management algorithm emphasizing early initiation of guideline-directed medical therapy, structured reassessment at 3 and 6 months, and individualized consideration of defibrillators, resynchronization therapy, arrhythmia ablation, transcatheter valve leaflet edge-to-edge repair, and advanced heart failure assessment. This document aims to support clinicians in risk stratification and timely management or referrals."}